| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
EG Life Sciences is a hybrid professional Life Sciences consulting services firm that provides Pharmaceutical, Biotechnology, and Medical device companies with the resources they need to meet the unique challenges of FDA regulated industries.
A new standard for virtual heart care. Heartbeat is a complete telehealth platform for cardiology that incorporates telemedicine, remote diagnostics, and digital heart health programs. Learn more
The American College of Veterinary Surgeons is the specialty board that defines the standards of surgical excellence for the field of veterinary medicine, promotes advancements in veterinary surgery, and provides the latest in veterinary surgical educa...
Cardiokine is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Philadelphia, PA. To find more information about Cardiokine, please visit www.cardiokine.com